The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates
Not Applicable
- Conditions
- Necrotizing Enterocolitis
- Interventions
- Other: placeboDietary Supplement: Docosahexaenoic Acid
- Registration Number
- NCT03700957
- Lead Sponsor
- Ain Shams University
- Brief Summary
The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in premature infants.
- Detailed Description
The efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in preterm neonates will be evalutaed through measuring its immune-modulatory effect on proinflammatory cytokines.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Preterm neonates having a gestational age equal or less than 34 weeks at birth.
- Weight (less than or equal 1.500 KG)
- Clinically stable to begin enteral feeding
Read More
Exclusion Criteria
- Persistent bleeding at any level.
- Receiving medication to avoid coagulation.
- Persistent vomiting.
- Gastrointestinal malformations.
- Mother taking Omega-3 supplements and planning to breastfeed.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Group placebo participants will recieve placebo Docosahexaenoic Acid Group Docosahexaenoic Acid participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
- Primary Outcome Measures
Name Time Method Efficacy of Docosahexaenoic Acid in reducing the incidence of Necrotizing Enterocolitis in premature infants. 10 days Monitoring the change in the serum levels of Interleukin-1 beta
- Secondary Outcome Measures
Name Time Method